You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK):將在2023年美國癌症研究協會年會上公佈三項最新臨牀前進展
格隆匯 03-15 07:42

格隆匯3月15日丨亞盛醫藥-B(06855.HK)發佈公吿,公司共有三項臨牀前研究進展入選2023年美國癌症研究協會年會(AACR 2023),包括公司已上市品種原創1類新藥-第三代BCR-ABL抑制劑奧雷巴替尼(耐立克®, HQP1351)、細胞凋亡管線重要在研品種Bcl-2抑制劑APG-2575和MDM2-p53抑制劑APG-115,將為新治療領域的探索奠定研究基礎。摘要內容現已在AACR官網公佈。

根據披露,美國癌症研究協會(AACR)年會是全球歷史最悠久、規模最大的腫瘤研究學術會議之一。會議關注高質量腫瘤研究及創新的各個方面,是全球腫瘤研究的焦點,將彙集腫瘤領域的最前沿的研究成果。本屆AACR年會將於美國東部時間2023年4月14日至4月19日在美國佛羅里達州奧蘭多舉行。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account